Furthermore, additional analysis of clinical trial data has revealed that the effectiveness of molecular targeted agents, such as anti-epidermal growth factor receptor and anti-vascular endothelial growth factor, depends on whether CRC is right-sided or left-sided [120,121]. The gene discussed is EGFR; the disease is colorectal carcinoma.